Table 2.

Summary of Phase 2 Clinical Trials With Selective RET Kinase Inhibitor for the Treatment of Patients with RET Fusion–Positive NSCLC

Author	RET Inhibitor	N	Platinum Exposed, N (%)	Detection Method (tissue)	ORR, % (95% CI; n)	PFS (Range)	DCR, %	Grade 3–4 TRAE, %
Gainor et al.201940	Pralsetinib	57	30 (53)	Nr	56 (32; -)	Nr	91	28
Drilon et al.201941	Selpercatinib	105	105 (100)	PCR, NGS	68 (71; 58–76)	18.4 (Nr)	94	Nr

CI, confidence interval; DCR, disease control rate; NGS, next-generation sequencing; Nr, not reported; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; PCR, polymerase chain reaction; TRAE, treatment-related adverse event.